Quick Answer
Janux Therapeutics, Inc. reported Stockholders Equity of $956.82 million for fiscal year 2025.
Janux Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $956.82M | -6.4% |
| 2024 | $1.02B | +197.0% |
| 2023 | $344.35M | +7.4% |
| 2022 | $320.74M | -12.4% |
| 2021 | $366.33M | +2602.6% |
| 2020 | -$14.64M | -84.3% |
| 2019 | -$7.94M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $976.55M | +48.8% | -1.4% |
| June 30, 2025 | $990.52M | +50.6% | -2.2% |
| March 31, 2025 | $1.01B | +54.4% | -1.0% |
| December 31, 2024 | $1.02B | +197.0% | +55.9% |
| September 30, 2024 | $656.10M | +88.0% | -0.2% |
| June 30, 2024 | $657.68M | +119.6% | +0.3% |
| March 31, 2024 | $655.76M | +110.7% | +90.4% |
| December 31, 2023 | $344.35M | +7.4% | -1.3% |
- Janux Therapeutics, Inc. showed a decrease of -6.4% in Stockholders Equity compared to the prior fiscal year.
- Over the 2019–2025 period, Janux Therapeutics, Inc.’s stockholders equity has grown by 12144.6% (from -$7.94 million to $956.82 million).
- The most recent figure is from Janux Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: